SYTL5 Promotes Papillary Thyroid Carcinoma Progression by Enhancing Activation of the NF-κB Signaling Pathway

Da Huang,Ying Zeng,Han-Yue Deng,Bi-Dong Fu,Yun Ke,Jing-Yi Luo,Ji-Chun Yu,Shi-Tong Yu
DOI: https://doi.org/10.1210/endocr/bqac187
IF: 5.051
2022-11-14
Endocrinology
Abstract:Abstract The function and mechanism of SYTL5 in papillary thyroid carcinoma (PTC) are still unclear. In this research, we found that SYTL5 was significantly overexpressed in PTC tissues compared with normal thyroid tissues. SYTL5 downregulation significantly weakened the proliferative, migratory, and invasive abilities of PTC cells. In addition, upregulated SYTL5 could promote cancer progression by activating the NF-κB signaling pathway. RAC1b expression is positively associated with SYTL5, and overexpressed RAC1b abrogated the antitumor effect after SYTL5 inhibition. In conclusion, our findings identify the oncogenic role of SYTL5 in PTC by activation of the NF-κB signaling pathway, thus facilitating PTC development and progression.
endocrinology & metabolism
What problem does this paper attempt to address?